Evidence map›Paper›PMID 34603017›Full record

ReviewFrontiers in pharmacology2021

Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy.

Wenjing Xiao, Qiaodan Zhou, Xudong Wen, Rui Wang, Ruijie Liu, Tingting Wang, Jianyou Shi, Yonghe Hu, Jun Hou

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Epigenetic reprogramming in cancer: From diagnosis to treatment.Frontiers in cell and developmental biology · 2023
    Review
  16. Alkyne Activation in the Diversity Oriented Synthesis of spChemistry (Weinheim an der Bergstrasse, Germany) · 2022
    Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Wenjing XiaoSchool of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Qiaodan ZhouDepartment of Ultrasonic, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xudong WenDepartment of Gastroenterology and Hepatology, Chengdu First People's Hospital, Chengdu, China.
Rui WangInformation Department of Medical Security Center, The General Hospital of Western Theater Command of PLA, Chengdu, China.
Ruijie LiuSchool of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Tingting WangSchool of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Jianyou ShiPersonalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yonghe HuSchool of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Jun HouSchool of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Chengdu Military General Hospital · CNSouthwest Jiaotong University · CNSichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer treatment is a significant challenge for the global health system, although various pharmacological and therapeutic discoveries have been made. It has been widely established that cancer is associated with epigenetic modification, which is reversible and becomes an attractive target for drug development. Adding chemical groups to the DNA backbone and modifying histone proteins impart distinct characteristics on chromatin architecture. This process is mediated by various enzymes modifying chromatin structures to achieve the diversity of epigenetic space and the intricacy in gene expression files. After decades of effort, epigenetic modification has represented the hallmarks of different cancer types, and the enzymes involved in this process have provided novel targets for antitumor therapy development. Epigenetic drugs show significant effects on both preclinical and clinical studies in which the target development and research offer a promising direction for cancer therapy. Here, we summarize the different types of epigenetic enzymes which target corresponding protein domains, emphasize DNA methylation, histone modifications, and microRNA-mediated cooperation with epigenetic modification, and highlight recent achievements in developing targets for epigenetic inhibitor therapy. This article reviews current anticancer small-molecule inhibitors targeting epigenetic modified enzymes and displays their performances in different stages of clinical trials. Future studies are further needed to address their off-target effects and cytotoxicity to improve their clinical translation.

Indexed as

cancer biomarkerepigenetic drugsepigenetic reprogramminghistone modificationmicroRNAsmall-molecule inhibitors

Identifiers

PMID34603017
PMCPMC8484527
OpenAlexW3199306263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.